Summit Therapeutics (SMMT) Return on Equity (2022 - 2024)
Historic Return on Equity for Summit Therapeutics (SMMT) over the last 9 years, with Q3 2025 value amounting to 0.29%.
- Summit Therapeutics' Return on Equity rose 200.0% to 0.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29%, marking a year-over-year increase of 200.0%. This contributed to the annual value of 1.01% for FY2024, which is 50100.0% up from last year.
- Latest data reveals that Summit Therapeutics reported Return on Equity of 0.29% as of Q3 2025, which was up 200.0% from 0.42% recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Return on Equity registered a high of 0.0% during Q3 2021, and its lowest value of 0.93% during Q1 2024.
- In the last 5 years, Summit Therapeutics' Return on Equity had a median value of 0.29% in 2025 and averaged 0.27%.
- In the last 5 years, Summit Therapeutics' Return on Equity crashed by -6400bps in 2024 and then surged by 5900bps in 2025.
- Summit Therapeutics' Return on Equity (Quarter) stood at 0.0% in 2021, then plummeted by 2000000000bps to 0.29% in 2022, then tumbled by -123bps to 0.64% in 2023, then surged by 52bps to 0.31% in 2024, then increased by 5bps to 0.29% in 2025.
- Its Return on Equity was 0.29% in Q3 2025, compared to 0.42% in Q2 2025 and 0.34% in Q1 2025.